Bioequivalence of 600mg dose of peramivir administered via intramuscular versus intravenous routes

Trial Profile

Bioequivalence of 600mg dose of peramivir administered via intramuscular versus intravenous routes

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Nov 2014

At a glance

  • Drugs Peramivir (Primary) ; Peramivir (Primary)
  • Indications Influenza virus infections
  • Focus Pharmacokinetics
  • Sponsors BioCryst Pharmaceuticals
  • Most Recent Events

    • 20 Nov 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top